Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
Year: 2020
Type: article
Study design: Observational Study
Abstract: Neutropenia is a common side effect associated with nab-paclitaxel gemcitabine (Nab-Gem) therapy. We retrospectively investigated the association between neutropenia induced by first-line Nab-Gem and survival in metastatic pancreatic carcinoma patients. Metastatic pancreatic patients treated with first-line Nab-Gem were included in this retrospective analysis. Neutropenia was categorized using the National Cancer Institute Common Toxicity Criteria scale. Outcome measures were overall survival (OS), progression-free survival (PFS) and response rate. 115 patients were analyzed. Median PFS was 7 months (95% CI 5-8) for patients with grade ≥ 3 neutropenia and 6 months (95% CI 5-6) for patients with grade < 3 neutropenia [p = 0.08; hazard ratio (HR 0.68)]. Median OS was 13 months (95% CI 10-18) for patients with grade ≥ 3 neutropenia and 10 months (95% CI 8-13) for patients with grade < 3 neutropenia (p = 0.04; HR 0.44). In multivariate analysis, the occurrence of grade ≥ 3 neutropenia showed a statistically significant association with OS (HR 0.62; 95% CI 0.09-0.86; p = 0.05). Nab-Gem-induced neutropenia is associated with longer survival in metastatic pancreatic cancer patients.
Source: Scientific Reports
Authors: Giandomenico Roviello(Conceptualization, Data curation, Software, Writing – original draft, Writing – review & editing), Monica Ramello(Writing – review & editing), Martina Catalano(Resources), Alberto D’Angelo, Raffaele Conca(Investigation, Resources), Silvia Gasperoni(Resources, Writing – original draft), Lorenzo Dreoni(Resources, Writing – original draft), Roberto Petrioli(Writing – original draft, Writing – review & editing), Anna Ianza(Resources), Stefania Nobili(Methodology), Michele Aieta(Validation, Writing – review & editing), Enrico Mini(Conceptualization, Formal analysis, Project administration, Supervision, Validation, Writing – review & editing)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,870
OpenAlex ID: W3096053571
